Biochemical and morphological characterization of the AβPP/PS/Tau triple transgenic mouse model and its relevance to sporadic alzheimer's disease

Journal of Alzheimer's Disease

Volumn 27, Issue 2, 2011, Pages 361-376

  Hunter, Jesse M ^a   Bowers, William J ^b   Maarouf, Chera L ^a   Mastrangelo, Michael A ^b   Daugs, Ian D ^a   Kokjohn, Tyler A ^a,c   Kalback, Walter M ^a   Luehrs, Dean C ^a   Valla, Jon ^c   Beach, Thomas G ^a   Roher, Alex E ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c MIDWESTERN UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; amyloid precursor protein; presenilin; tau; transgenic mice

Indexed keywords

AMYLOID PRECURSOR PROTEIN; PRESENILIN 1; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL TISSUE; ARTICLE; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; MALE; MORPHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 81855211122     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110608     Document Type: Article

References (45)

1. Bekris LM, Yu CE, Bird TD, Tsuang DW (2010) Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol 23, 213-227.
2. Verghese PB, Castellano JM, Holtzman DM (2011) Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol 10, 241-252.
3. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421. (Pubitemid 36937044)
4. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM (2003) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 24, 1063-1070. (Pubitemid 37487883)
5. Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, LaFerla FM (2006) Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem 281, 39413-39423. (Pubitemid 46041901)
6. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Abeta immunotherapy leads to clearance of early, butnot late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43, 321-332. (Pubitemid 39061125)
7. Roher AE, Maarouf CL, Daugs ID, Kokjohn TA, Hunter JM, Sabbagh MN, Beach TG (2011) Neuropathology and Afj Spectrum in a Bapineuzumab Immunotherapy Recipient. J Alzheimers Dis 24, 315-325.
8. Maarouf CL, Daugs ID, Kokjohn TA, Kalback WM, Patton RL, Luehrs DC, Masliah E, Nicoll JA, Sabbagh MN, Beach TG, Castano EM, Roher AE (2010) The biochemical aftermath of anti-amyloid immunotherapy. Mol Neurodegener 5, 39.
9. Boche D, Denham N, Holmes C, Nicoll JA (2010) Neuropathology after active Abeta42 immunotherapy: Implications for Alzheimer's disease pathogenesis. Acta Neuropathol 120, 369-384.
10. Kokjohn TA, Roher AE (2009) Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions. Alzheimers Dement 5, 340-347.
11. Kokjohn TA, Roher AE (2009) Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial. CNS Neurol Disord Drug Targets 8, 88-97.
12. Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, Wilkinson D, Holmes C, Nicoll JA (2008) Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 131, 3299-3310.
13. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet 372, 216-223. (Pubitemid 351978111)
14. Beach TG, Sue LI, Walker DG, Roher AE, Lue L, Vedders L, Connor DJ, Sabbagh MN, Rogers J (2008) The Sun Health Research Institute Brain Donation Program: Description and experience, 1987-2007. Cell Tissue Bank 9, 229-245.
15. Mirra SS (1997) The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: A commentary. Neurobiol Aging 18, S91-S94. (Pubitemid 27454705)
16. Mastrangelo MA, Bowers WJ (2008) Detailed immunohisto-chemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice. BMC Neurosci 9, 81.
17. Mastrangelo MA, Sudol KL, Narrow WC, Bowers WJ (2009) Interferon-{gamma} differentially affects Alzheimer's disease pathologies and induces neurogenesis in triple transgenic-AD mice. Am J Pathol 175, 2076-2088.
18. Ryan DA, Mastrangelo MA, Narrow WC, Sullivan MA, Federoff HJ, Bowers WJ (2010) Abeta-directed single-chain antibody delivery via a serotype-1 AAV vector improves learning behavior and pathology in Alzheimer's disease mice. Mol Ther 18, 1471-1481.
19. Maarouf CL, Daugs ID, Spina S, Vidal R, Kokjohn TA, Pat-ton RL, Kalback WM, Luehrs DC, Walker DG, Castano EM, Beach TG, Ghetti B, Roher AE (2008) Histopathological and molecular heterogeneity among individuals with dementia associated with Presenilinmutations. Mol Neurodegener 3, 20.
20. Van Vickle GD, Esh CL, Daugs ID, Kokjohn TA, Kalback WM, Patton RL, Luehrs DC, Walker DG, Lue LF, Beach TG, Davis J, Van Nostrand WE, Castano EM, Roher AE (2008) Tg-SwDI transgenic mice exhibit novel alterations in AbetaPP processing, Abeta degradation, and resilient amyloid angiopathy. Am J Pathol 173, 483-493.
21. Oh KJ, Perez SE, Lagalwar S, Vana L, Binder L, Mufson EJ (2010) Staging of Alzheimer's pathology in triple trans-genic mice: A light and electron microscopic analysis. Int J Alzheimers Dis 2010.
22. Rodriguez JJ, Jones VC, Tabuchi M, Allan SM, Knight EM, LaFerla FM, Oddo S, Verkhratsky A (2008) Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's disease. PLoS One 3, e2935.
23. Overk CR, Kelley CM, Mufson EJ (2009) Brainstem Alzheimer's-like pathology in the triple transgenic mouse model of Alzheimer's disease. Neurobiol Dis 35, 415-425.
24. Puente XS, Sanchez LM, Overall CM, Lopez-Otin C (2003) Human and mouse proteases: A comparative genomic approach. Nat Rev Genet 4, 544-558. (Pubitemid 36781345)
25. Puente XS, Lopez-Otin C (2004) A genomic analysis of rat proteases and protease inhibitors. Genome Res 14, 609-622. (Pubitemid 38500232)
26. Loerch PM, Lu T, Dakin KA, Vann JM, Isaacs A, Geula C, Wang. J, Pan Y, Gabuzda DH, Li C, Prolla TA, Yankner BA (2008) Evolution of the aging brain transcriptome and synaptic regulation. PLoS One 3, e3329.
27. Handler M, Yang X, Shen J (2000) Presenilin-1 regulates neu-ronal differentiation during neurogenesis. Development 127, 2593-2606. (Pubitemid 30426807)
28. Parks AL, Curtis D (2007) Presenilin diversifies its portfolio. Trends Genet 23, 140-150. (Pubitemid 46275145)
29. Ghosal K, Vogt DL, Liang M, Shen Y, Lamb BT, Pimplikar SW (2009) Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc Natl Acad Sci USA 106, 18367-18372.
30. Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M (2009) APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457, 981-989.
31. Lehman EJ, Kulnane LS, Gao Y, Petriello MC, Pimpis KM, Younkin L, Dolios G, Wang R, Younkin SG, Lamb BT (2003) Genetic background regulates beta-amyloid precursor protein processing and beta-amyloid deposition in the mouse. Hum Mol Genet 12, 2949-2956. (Pubitemid 37442023)
32. Davis J, Xu F, Deane R, Romanov G, Previti ML, Zeigler K, Zlokovic BV, Van Nostrand WE (2004) Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J Biol Chem 279, 20296-20306. (Pubitemid 38623475)
33. Van Vickle GD, Esh CL, Kalback WM, Patton RL, Luehrs DC, Kokjohn TA, Fifield FG, Fraser PE, Westaway D, McLaurin J, Lopez J, Brune D, Newel AJ, Poston M, Beach TG, Roher AE (2007) TgCRND8 amyloid precursor protein transgenic mice exhibit an altered gamma-secretase processing and an aggressive, additive amyloid pathology subject to immunotherapeutic modulation. Biochemistry 46, 10317-10327. (Pubitemid 350067625)
34. Gray EG, Paula-Barbosa M, Roher A (1987) Alzheimer's disease: Paired helical filaments and cytomembranes. Neu-ropathol Appl Neurobiol 13, 91-110. (Pubitemid 17115921)
35. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, deCalignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT (2008) Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 451, 720-724. (Pubitemid 351220570)
36. Roher AE, Palmer KC, Capodilupo J, Wakade AR, Ball MJ (1991) New biochemical insights to unravel the pathogenesis of Alzheimer's lesions. Can J Neurol Sci 18, 408-410.
37. Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, Cotter RJ, Reardon IM, Zurcher-Neely HA, Heinrikson RL, Ball MJ, Greenberg BD (1993) Structural alterationsin the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 268, 3072-3083. (Pubitemid 23070928)
38. Roher AE, Palmer KC, Yurewicz EC, Ball MJ, Greenberg BD (1993) Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. J Neurochem 61, 1916-1926. (Pubitemid 23317220)
39. Nielsen HM, Mulder SD, Belien JA, Musters RJ, Eikelen-boom P, Veerhuis R (2010) Astrocytic A beta 1-42 uptake is determined by A beta-aggregation state and the presence of amyloid-associated proteins. Glia 58, 1235-1246.
40. Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O'Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC (2011) Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 69, 181-192.
41. Armstrong RA (2006) Plaques and tangles and the pathogen-esis of Alzheimer's disease. Folia Neuropathol 44, 1-11.
42. Neve RL, Robakis NK (1998) Alzheimer's disease: A re-examination of the amyloid hypothesis. Trends Neurosci 21, 15-19. (Pubitemid 128766369)
43. Dickson DW, Crystal HA, Mattiace LA, Masur DM, Blau AD, Davies P, Yen SH, Aronson MK (1992) Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging 13, 179-189.
44. Bouras C, Hof PR, Giannakopoulos P, Michel JP, Morrison JH (1994) Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: A quantitative evaluation of a one-year autopsy population from a geriatric hospital. Cereb Cortex 4, 138-150. (Pubitemid 24127824)
45. Giannakopoulos P, Hof PR, Surini M, Michel JP, Bouras C. (1993) Quantitative immunohistochemical analysisofthe distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of nonagenarians and centenarians. Acta Neu-ropathol 85, 602-610. (Pubitemid 23212026)